LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and AI solutions for Latin America, has announced a new agreement with DROGUERIAS LALA C.A., a Venezuelan pharmaceutical distributor, to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory workflows. The collaboration, formalized through LataMed’s Venezuelan subsidiary LATAMEDAI VE, aims to create customized technology that supports research, testing, quality control, documentation, and data analysis.
Under the agreement, the parties will jointly design, develop, test, and evaluate software intended to streamline operations in pharmaceutical and laboratory settings. Planned features include workflow automation, testing coordination, document management, data review, and predictive analytics that could help professionals identify inconsistencies earlier. The technology is designed as a decision-support tool, not a replacement for professional judgment, and will not independently approve formulas or regulatory submissions.
Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the significance of the partnership: “This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight.”
The move signals LataMed’s expansion beyond its patient-facing telemedicine services into enterprise applications. The company believes this collaboration could provide a framework adaptable for other pharmaceutical and healthcare organizations across Latin America, pending successful development and separate agreements.
The agreement outlines a phased approach: the parties will first identify specific workflows to address, define technical requirements, and establish development and testing processes. They will also set up confidentiality and data-management protocols. Intellectual property ownership and licensing terms will be determined separately.
This partnership is part of LataMed’s broader strategy to build digital infrastructure and AI tools for the healthcare ecosystem, including providers, pharmacies, and laboratories. The company is also developing AI platforms like CardioAI, PulmoAI, and NeuroAI, though these remain in development and subject to regulatory approvals.
While the potential benefits are significant, the agreement does not guarantee a specific implementation schedule or commercial deployment. The company cautioned that any future expansion would depend on successful testing, regulatory compliance, and market needs. LataMed also reiterated that its technologies are under development and are not intended to replace professional judgment.
For more information, visit https://latamed.ai or review the company’s SEC filings at www.sec.gov.
